Italy Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061615167
  • Pages : 88

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Diabetes patients have free access to all the medications, equipment, and healthcare services they require. Generally, Italy has a highly developed system for treating diabetes, with several diabetes facilities spread out over the nation and free care provided at the point of delivery. The majority of administrative and organizational authority in the Italian healthcare system is held by the Regions. The National Diabetes Plan, which has a patient-centered orientation, establishes goals and offers guidance for improving the standard of diabetes treatment. Comparing a routine examination of blood glucose levels at predetermined intervals to the current CGM devices reveals a thorough picture of blood glucose patterns and trends. Bypassing many of the drawbacks of self-monitoring blood glucose (SMBG) by fingerstick, these methods enable checking glucose management in diabetes in addition to HbA1c.

Increasing patients with Type-1 diabetes in Italy to surge growth.

Many difficulties are presented by diabetes for both the NHS and Italian society. The biggest problem is the growing incidence of diabetes, which will soon be a serious health and financial threat to the Italian healthcare system. For the past ten years, prevalence has been rising gradually, and this trend is projected to continue. According to some reports, if prevalence keeps increasing at this rate, its effects on society and the economy would become unsustainable. Aging populations are challenging to manage. According to the Medical Annals, obesity has grown in recent years due mostly to improper lifestyle decisions such as inadequate food and insufficient exercise. Because of their close relationship, obesity, and diabetes are together referred to as "diabesity". As diabetes incidence develops, it is getting harder to meet the demand for care, with diabetes clinics finding it challenging to treat a growing number of diabetic patients.

CGM sensors to surge the market in Italy.

The current continuous glucose monitoring systems may either download the data and retroactively display patterns in blood glucose levels or provide receiver displays with real-time glucose readings. The development of cutting-edge online applications, like hypo/hyperglycemia alert systems and artificial pancreas closed-loop control algorithms, has been sparked by the continuous glucose monitoring (CGM) sensors, which have opened up new scenarios for evaluating the effectiveness of individual patient therapeutic plans offline. With the development of new technology, continuous glucose monitoring devices are becoming more affordable.

Market Key Developments

  • In March 2023, FDA approved the FreeStyle Libre 2 and FreeStyle Libre 3 modified CGM (continuous glucose monitoring) system sensors as said by Abbott Laboratories for connection with automated insulin delivery (AID) systems.
  • In March 2022, DexCom stated that their G7 CGM system, intended for patients with diabetes two years of age and older, including pregnant women, in Italy, had received the CE Mark.

Italy Continuous Glucose Monitoring (CGM) Market Scope:


Report Metric Details
Growth Rate CAGR during the forecast period
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered Application and End-User Industry
Companies Covered Dexcom, Inc., Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Inc., Senseonics Holdings, Inc., Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care, Inc., GlucoMen, Diabeloop
Customization Scope Free report customization with purchase



  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End-User Industry
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients


6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care


7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix


8.1. Dexcom, Inc.

8.2. Abbott Laboratories

8.3. Medtronic plc

8.4. Roche Diabetes Care, Inc.

8.5. Senseonics Holdings, Inc.

8.6. Ascensia Diabetes Care

8.7. Insulet Corporation

8.8. Tandem Diabetes Care, Inc.

8.9. GlucoMen

8.10. Diabeloop

Dexcom, Inc.

Abbott Laboratories

Medtronic plc

Roche Diabetes Care, Inc.

Senseonics Holdings, Inc.

Ascensia Diabetes Care

Insulet Corporation

Tandem Diabetes Care, Inc.



Related Reports

Report Name Published Month Get Sample PDF